Dear Editor,
My colleagues and I are pleased to submit our response to the Song et al. [1] letter to the editor, which discussed perceived limitations and weaknesses of our comparison of inotuzumab ozogamicin (InO) vs. blinatumomab (Blina) for relapsed/refractory acute lymphoblastic leukemia (ALL).
ALL is a rare hematologic malignancy with a high rate of disease recurrence. No head-to-head studies have compared InO with Blina in adults with relapsed or refractory ALL; therefore, indirect treatment comparisons were used to assess the relative efficacy of these new therapies.
In our analyses, we could not fully adjust for the number of salvage therapies, but we did adjust for Philadelphia chromosome-positive (Ph?) B precursor status. Furthermore, our analysis provides a comparison of additional important outcomes, such as remission rate [defined as complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete hematologic recovery (CRi)], hematopoietic stem cell transplantation (HSCT), and eventfree survival (EFS). This is in contrast with the analysis in Song et al., which compared only overall survival (OS) and CR rates. CR and CRi are important measures of efficacy as patients can achieve minimal residual disease (MRD) negativity and proceed to HSCT, the only potentially curative treatment modality available, thus providing the benefit of long-term survival.
Our detailed responses to each concern raised by Song et al. in the Letter to the Editor are included below.
For the first point, ''the discrepancy in the number of prior salvage therapies is a fundamental difference between the two trial populations and without matching the number of prior salvage therapies, bias in favor of InO was introduced in Proskorovsky et al.,'' we acknowledge this limitation in several places in the manuscript. The number of prior salvage therapies is a prognostic factor and potential treatment effect modifier. However, since our analyses were anchored, only a treatment effect modification would introduce a potential bias because of the inability to adjust for two or more prior salvage therapies [2] . Forest plots for OS and the remission rate from the TOWER publication showed that, for OS, the effect of Blina vs. standard of care (SOC) was weaker in third-line plus patients [i.e., the hazard ratio (HR) and 95% confidence interval (CI) were 0.60 (0.39-0.91) for the first line, 0.59 (0.38-0.91) for the second line, and 1.13 (0.64-1.99) for the third line]. For remission rate, the opposite was observed; the odds ratio (OR; 95% CI) for the remission rate for Blina vs. SOC was 2.03 (1.08-3.80) in first line, 3.37 (1.35-8.38) in second line, and 4.10 (1.11-15.12) in third-line salvage.
The effect of Blina vs. SOC for EFS and HSCT in first and later salvage in TOWER was recently published by Dombret et al. [3] . The results showed a stronger treatment effect for Blina vs. SOC for EFS and HSCT for patients in secondline or later salvage. These findings suggest that failing to adjust for two or more lines of prior salvage therapies in the indirect treatment comparison ( In contrast, HSCT rates in TOWER were similar between Blina (24.0%) and SOC (23.9%), with an OR (95% CI) of 1.01 (0.62-1.63). A key function of treatment in relapsed or refractory ALL is the ability of patients to bridge to transplant; among those transplanted, InO showed better efficacy. As discussed in our original publication, in INO-VATE-ALL, the separation in OS curves between InO and SOC accelerated at 15 months, indicating a longer term survival benefit, consistent with the higher HSCT rates among patients in the InO arm. For the TOWER study, the OS curves for Blina and SOC converged around this same time point for the intention-to-treat population, consistent with the identical HSCT rates observed among patients in the Blina and SOC arms. However, due to limited follow-up in the TOWER study, making the assessment of long-term OS data is difficult.
Furthermore, for the comparison of OS, similar considerations apply (i.e., OS can be impacted by subsequent therapies and other factors outside of the trial), but Song et al. conducted not only anchored but also unanchored MAIC analyses for OS.
As to the third point raised by Song et al.adjusting only for select variables in anchored MAIC for each outcome in the analyses by Proskorovsky et al.-the selection of potential treatment effect modifiers was carefully approached; we examined available forest plots from the INO-VATE-ALL and TOWER studies and obtained clinical input. In anchored analyses, adjusting for all available patient characteristics (i.e., prognostic factors and treatment effect modifiers) can lead to a substantial reduction in the effective sample size (ESS), which translates to a loss of precision of the estimated treatment effect without an additional bias reduction [4] . The National Institute for Health and Care Excellence Decision Support Unit recommendation clearly states that for anchored comparison, only treatment effect However, in response to this letter, we conducted additional exploratory analyses for OS and EFS that adjusted for additional baseline patient characteristics (i.e., age, region, previous allogeneic HSCT, Ph ? B precursor, duration of first remission, salvage treatment phase, maximum of central/local bone marrow blasts, hemoglobin, and platelets). Results of these analyses are presented in Table 2 ; they show that the point estimates for the treatment effect of InO vs. Blina for EFS and OS were similar to the previously published results. However, as expected, including additional variables in the adjustment reduced the precision and widened the 95% CIs around the estimated treatment effects.
In conclusion, the analyses by Proskorovsky et al. are not without limitations; however, they are articulated in the discussion section of the paper. In our opinion, the questions raised by Song 
